12 results about "Abnormal glucose" patented technology

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The invention provides emblic leafflower fruit polysaccharide with a weight losing effect and an efficient preparation method and application thereof, and belongs to the field of plant polysaccharide. The preparation method comprises the following steps: performing powdering, water extraction and concentration on a phyllanthus emblica raw material, adding an alcohol solvent for precipitation, and drying to obtain phyllanthus emblica crude polysaccharide; after the phyllanthus emblica crude polysaccharide is dissolved, impurities are removed through membrane filtration, protein substances are adsorbed through a reversed-phase chromatographic column, flow-through liquid and water leacheate are collected and combined, small-molecular-weight substances are removed through a membrane bag, intercepted liquid is collected and dried, and the phyllanthus emblica polysaccharide is obtained. The phyllanthus emblica polysaccharide has alpha-type and beta-type glycosidic bonds, and has linear polysaccharide chains and aggregates formed by a plurality of chains. The emblic leafflower fruit polysaccharide is used for preparing products for reducing fat and blood sugar, and can also be used for preparing medicines for preventing and treating abnormal glucose metabolism, abnormal lipid metabolism, related diseases, obesity and liver injury caused by obesity. The phyllanthus emblica polysaccharide extraction and purification preparation method is simple and efficient, and is convenient for industrial implementation.

The application provides a traditional Chinese medicine composition for preventing and treating metabolic-related fatty liver disease combined with type 2 diabetes and application thereof, and the traditional Chinese medicine composition is made of raw materials in the following weight parts: 6-30 parts of Huangqi, 0-20 parts of Ganjiang, 4-20 parts of Shaoyao, 4-20 parts of Gancao and 2-30 parts of Dazao. The medicine provided by the application can simultaneously significantly improve the abnormal glucose metabolism and liver metabolism damage of a "sugar-liver comorbidity" model animal, realizes integrated intervention on a core pathological link of the disease, can produce an unexpected integrated treatment effect on the "sugar-liver comorbidity", significantly reduces adverse reactions of diarrhea, improves gastrointestinal tolerance, is more suitable for the core pathogenesis of the "sugar-liver comorbidity" with cold and heat mixed together, and is beneficial to improving long-term medication safety.

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

The invention belongs to the field of genetic engineering animal models, and particularly relates to a specific Foxp4 gene knockout mouse model and a construction method and application thereof. The method comprises the following steps: by utilizing a Cre-loxP system, obtaining Foxp4-fl / fl from a Foxp4-fl / fl from a Foxp4-fl / + heterozygote mouse and an Alb-Cre mouse through a mating strategy; and the liver-specific Foxp4 knockout mouse model is constructed by using the Foxp4 knockout mouse and an Albcre / + mouse. The invention finds for the first time that the Foxp4 plays an important role in maintaining the steady state function of the liver, the deficiency of the Foxp4 leads to phenotypes such as lipid accumulation in the liver, inflammatory cell infiltration, liver cell function damage, mild fibrosis and abnormal glucose and lipid metabolism, and the phenotypes are highly consistent with early symptoms and molecular characteristics of NAFLD; the Foxp4 gene has important application value in the aspects of researching the effect of the Foxp4 gene in the occurrence and development mechanism of the NAFLD and the maintenance of liver homeostasis, developing NAFLD-related therapeutic drugs and the like.

The invention discloses a medium-chain and long-chain fatty acid grease-probiotic composition and application thereof in regulating blood sugar and blood lipid, the composition comprises a grease component and a probiotic component, the grease component takes myristic acid as main fatty acid, MA accounts for 50-70% of the total amount of fatty acid in grease, and the grease component is compounded with medium-chain triglyceride and high-oleic-acid sunflower seed oil. And the probiotic component is bifidobacterium pseudocatenum, and the viable count of the bifidobacterium pseudocatenum is preferably 1 * 10 < 9 >-1 * 10 < 11 > CFU / g. Animal experiments verify that the composition can significantly reduce fasting blood-glucose, improve oral glucose tolerance damage and significantly reduce serum total cholesterol and triglyceride levels. Compared with single use of MA grease or single use of Bifidobacterium pseudocatenuicola, the composition provided by the invention shows a better comprehensive effect in the aspects of regulating blood sugar and blood fat, can be applied to functional foods, nutritional supplements and pharmaceutical preparations, and is used for preventing or assisting in improving abnormal glucose and lipid metabolism.

The invention relates to the field of microorganisms, in particular to application of Cristinia parvata in preparation of products for preventing and / or improving obesity and / or glucose and lipid metabolism disorder. The invention provides Christsenella minuta, and the preservation number of the Christsenella minuta is CGMCC (China General Microbiological Culture Collection Center) No.46901. The invention also provides a preparation method of the Christsenella minuta. The Cristsenella minuta provided by the invention can effectively inhibit the serum uric acid value of an organism, reduce the blood sugar level, improve reproductive injury caused by abnormal metabolism, effectively regulate and control abnormal glucose and lipid metabolism, and can improve symptoms such as obesity and / or hyperuricemia and / or gout diseases.

The invention discloses a medicine for treating hepatotoxicity of bosutinib by taking a CAMK2G gene or protein as a target spot, and belongs to the technical field of medicines. According to the medicine, the hepatotoxicity of bosutinib is relieved by down-regulating the expression of the CAMK2G gene or restoring the phosphorylation of the CAMK2G protein. The invention reveals that the CAMK2G gene is a key gene of liver injury and abnormal glucose metabolism caused by bosutinib, and provides a new prevention and treatment target for intervening hepatotoxicity caused by bosutinib. According to the invention, the CAMK2G phosphorylation activator is utilized to recover CAMK2G phosphorylation to relieve liver injury and abnormal glucose metabolism, a new direction is provided for finding an intervention strategy for causing hepatotoxicity by drugs, and the current situation that few intervention drugs can be used clinically and the mechanism is single is solved to a certain extent.

A use of INHBC as a target in the prevention and / or treatment of a metabolic disease. Provided is a use of a substance promoting the expression of an INHBC gene or improving the activity of an INHBC protein in the preparation of a product for preventing and / or treating a metabolic disease, wherein the metabolic disease comprises an energy metabolism dysfunction-induced disease, such as obesity, diabetes, fatty liver disease, or hyperlipidemia. Liver-specific overexpression or knock-in of INHBC can relieve liver steatosis and abnormal glucose metabolism in mice induced by a high-fat diet, and can also enhance the thermogenic activity of adipose tissues in the mice, thereby inhibiting obesity induced by the high-fat diet, showing significant application value in the prevention and / or treatment of metabolic diseases such as obesity, type 2 diabetes, and fatty liver diseases.

The application discloses application of 3-demethylcolchicine in medicine, and experiment proves that the 3-demethylcolchicine can obviously reduce the body weight and liver weight of NAFLD mice, can obviously reduce the liver injury and liver lipid deposition of the NAFLD mice, and can improve the liver function and abnormal glucose metabolism of the NAFLD, and has a wide application prospect in NAFLD medicine.

This invention discloses a traditional Chinese medicine composition and its application for treating various symptoms caused by spleen deficiency and stomach heat, with warming the spleen yang as the core of the formula. This invention reveals for the first time that modern people, due to excessive intake of animal-based foods, experience excessive stomach heat and a preference for cold foods, repeatedly damaging the spleen yang and forming a pathogenesis of "spleen deficiency and stomach heat," leading to various symptoms such as thirst, dry phlegm, dry and congested nose, obesity or emaciation, and abnormal glucose metabolism. Currently, Western medicine has no radical cure, and traditional Chinese medicine adheres to the theory of diabetes, resulting in poor efficacy. This invention innovatively uses warming the spleen yang as the core of the formula, creating a new formula based on the Da Bu Pi Tang (Great Spleen-Tonifying Decoction) in the *Fu Xing Jue* (Auxiliary Formula). It consists of herbs such as Codonopsis pilosula, prepared licorice root, dried ginger, Ophiopogon japonicus, Schisandra chinensis, Curcuma zedoaria, and Inula japonica. The formula has a rigorous combination of principal, assistant, and adjuvant herbs, warming the spleen without promoting heat and clearing away dampness without harming yang, precisely targeting the pathogenesis of spleen deficiency and stomach heat in modern people. This invention can be formulated into various oral dosage forms, with a simple formula, strong targeting, and high clinical value.

The invention discloses a compound dietary fiber low-GI steamed stuffed bun and a preparation method thereof, and belongs to the technical field of functional foods.Whole wheat flour is used as a main raw material, a dietary fiber composition formed by compounding soluble dietary fibers and insoluble dietary fibers according to a specific proportion is matched, a mulberry leaf extract and compound lactic acid bacteria powder are added in a synergistic mode, and the low-GI steamed stuffed bun is prepared. And step-type fermentation and steaming processes are combined, so that the steamed bun is prepared. Wherein the soluble dietary fiber is selected from resistant dextrin, fructo-oligosaccharide or inulin, and the insoluble dietary fiber is selected from oat fiber, wheat bran or pea fiber. Through collaborative optimization of dietary fiber types and proportions, functional ingredients and fermentation process conditions, the obtained steamed stuffed bun keeps good formability, tissue structure and processing adaptability, and meanwhile, the starch digestion rate is effectively reduced, so that a low glycemic index and a low blood sugar load are realized; the product disclosed by the invention is suitable for people with abnormal glucose metabolism and people with healthy diet requirements to eat, and has a good industrial application prospect.